Syndax Pharmaceuticals
SNDX
160 hedge funds and large institutions have $1.78B invested in Syndax Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 65 increasing their positions, 41 reducing their positions, and 10 closing their positions.
220% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 10
59% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 41
28% more capital invested
Capital invested by funds: $1.39B → $1.78B (+$393M)
15% more funds holding
Funds holding: 139 → 160 (+21)
10% more funds holding in top 10
Funds holding in top 10: 10 → 11 (+1)
8% more call options, than puts
Call options by funds: $2.77M | Put options by funds: $2.56M
0.59% more ownership
Funds ownership: 105.87% → 106.47% (+0.59%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$83.9M |
| 2 |
State Street
Boston,
Massachusetts
|
+$24M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$21.5M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
+$20.3M |
| 5 |
Barclays
London,
United Kingdom
|
+$16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$19M |
| 2 |
HM
HealthCor Management
New York
|
-$18.4M |
| 3 |
6CM
683 Capital Management
New York
|
-$13.1M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$9.32M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
-$8.09M |
SNDX Hedge Fund Activity: Q4 2022 in Review
160 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q4 2022, worth a combined $1.78B — up 28% from $1.39B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new SNDX positions and 10 closed out — a net gain of 22 holders — while 65 added to existing stakes and 41 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $83.9M. The largest seller was Woodline Partners, exiting entirely with an estimated $19M sold.
- 160 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q4 2022, up from 139 in Q3 2022.
- Funds reported $1.78B of Syndax Pharmaceuticals stock for Q4 2022, up 28% quarter-over-quarter.
- 32 funds opened new Syndax Pharmaceuticals positions in Q4 2022 and 10 closed out, a net change of +22 holders.
- The largest Syndax Pharmaceuticals buyer in Q4 2022 was Wellington Management Group, an estimated $83.9M added.
- The largest Syndax Pharmaceuticals seller in Q4 2022 was Woodline Partners, an estimated $19M sold.
Based on aggregated 13F filings for Q4 2022.